Synbio International, Inc. (OTC: SYIN) has taken a significant step toward generating revenue by entering into a Strategic Licensing, Manufacturing, Supply and Revenue Sharing Agreement with MD PHD Wellness, Inc. The deal grants Synbio exclusive rights to commercialize MD PHD Wellness' proprietary nutraceutical formulations across the United States and Canada. This partnership is pivotal for Synbio as it allows the company to bypass the lengthy and costly process of developing products from scratch, thereby fast-tracking its entry into the lucrative nutraceutical market.
The agreement covers MD PHD Wellness' flagship anti-anxiety nutraceutical formulation, which will be marketed under Synbio's Healing Force™ brand. It also sets a framework for evaluating and commercializing additional wellness products in the future, ensuring a long-term product pipeline. Under the terms, MD PHD Wellness will manage product development, manufacturing, quality assurance, and supply chain, while Synbio will focus on branding, marketing, sales, and distribution. Profits from product sales will be shared after recovering approved manufacturing and commercialization costs.
Claudio Solitario, CEO of Synbio International, described the agreement as a "transformational milestone." He highlighted that the partnership combines MD PHD's expertise in product development and manufacturing with Synbio's commercialization capabilities, providing immediate access to proprietary products that can generate near-term revenue. This model is both efficient and scalable, positioning Synbio to capitalize on the expanding global nutraceutical market while continuing to develop its AI-driven healthcare technologies.
MD PHD Wellness brings scientific leadership to the table. Founded by Dr. Robert Lawrence, a physician and scientist with Ph.D.s in Nuclear Physics and Biomedical Engineering, the company has a strong foundation in nutraceutical development. Dr. Lawrence's research spans cellular regeneration, natural product delivery systems, and pharmaceutical applications. Co-founder Dr. David Anderson, an experienced physician and researcher, played a key role in developing the licensed formulations. His background includes work as a Research Physician and Senior Research Scientist at a prominent New York university, where he evaluated therapeutics and nutraceuticals. His contributions have been recognized in Marquis Who's Who.
This licensing agreement is a strategic move for Synbio as it builds a diversified healthcare company. The company aims to pair near-term revenue from wellness products with longer-term value from its AI-driven mental health technologies, which use facial analysis to screen for mental health conditions. This dual-track approach provides multiple growth avenues and supports continued investment in innovation. Synbio plans to launch its nutraceutical products online in 2026, with the goal of creating shareholder value through brand building and market expansion.
For more information about Synbio International and its initiatives, visit www.synbiointl.com.
